Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 742.00

-0.7%

11:09 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (915)	4/2/2004 8:23:53 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

Early, and somewhere here at SI I mentioned that Trap bind at least three VEGF form (A-C), due to fact that it is construct of the R1 and R2 receptor. Seams that I was wrong in my assumption. At least not as potently as for VEGF-A,B Trap does not bind C and D at lower conc. jci.org Table1. and graph indicate no binding for VEGF-C/D jci.org jci.org While article deal with VEGF-A rule in corneal hemangiogenesis and lymphangiogenesis, is it possible to translate finding in cancer model field, cancer biology? Interesting that Avastin (which bind C and D even with lower potency relative to Trap, again my assumption) did not generate benefit in late stage metastatic breast cancer (highly lymphangiogenic). Now the question is why Avastin did work in naive metastatic CRC and will it work in metastatic NSCLC????? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next